Welcome to our dedicated page for Marpai SEC filings (Ticker: MRAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Marpai, Inc. (MRAI) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Marpai’s filings describe its business as a technology platform company operating subsidiaries that provide Third-Party Administration (TPA), Pharmacy Benefit Management (PBM) and value-oriented health plan services to employers that directly pay for employee health benefits. Its Class A common stock is listed on the OTCQX Market under the symbol MRAI.
Through periodic and current reports, Marpai presents financial statements, details of its operating performance and information about its capital structure. For example, Form 8-K filings included in this record describe private placements of Class A common stock and warrants under Securities Purchase Agreements, with proceeds intended for working capital and general corporate purposes. Other 8-K filings reference amendments to the company’s certificate of incorporation, such as the authorization of blank-check preferred stock, and the release of selected financial information for specific reporting periods.
Annual proxy materials, such as the definitive proxy statement (DEF 14A), outline governance matters, including the election of directors, ratification of the independent registered public accounting firm and proposals to amend the certificate of incorporation. These documents also confirm key facts such as Marpai’s Delaware incorporation, its Tampa, Florida office location and the voting rights associated with its Class A common stock.
On this page, users can review Marpai’s Forms 10-K and 10-Q (when available), current reports on Form 8-K, proxy statements and other filings. Stock Titan’s tools can surface summaries and key points from longer documents, helping readers understand topics such as equity issuances, changes to the capital structure, governance proposals and how Marpai presents its TPA and PBM operations in official filings.
Marpai, Inc. (MRAI) director purchase disclosed. A director reported buying 100,000 shares of Class A common stock at $1.00 per share in a private placement on November 7, 2025, and received common warrants to purchase up to 200,000 additional shares at an exercise price of $1.00.
The warrants are exercisable immediately and remain exercisable until November 6, 2028. Following the transaction, the director directly owns 1,089,073 shares.
Marpai (MRAI) reported an insider transaction by a director. On 11/07/2025, the reporting person purchased 50,000 shares of Class A common stock at $1.00 per share and acquired common warrants for up to 100,000 shares with a $1.00 exercise price. The warrants are exercisable immediately and expire on 11/06/2028. Following the transaction, the insider beneficially owned 272,000 shares, held directly.
Marpai, Inc. (MRAI) insider transaction: Chief Operating Officer Dallas Scrip reported a private placement purchase on 11/07/2025 of 100,000 shares of Class A common stock at $1.00 per share and common warrants to purchase up to 200,000 additional shares. The warrants are exercisable immediately at $1.00 per share and remain exercisable for three years from the 11/07/2025 issuance date, expiring on 11/06/2028.
The securities are held indirectly by the Dallas S. Scrip and Michelle R. Script Trust, for which the reporting person and spouse serve as co‑trustees with shared voting and investment control.
Marpai, Inc. (MRAI) reported an insider purchase by director Robert Pons. On November 7, 2025, he bought 50,000 shares of Class A common stock in a private placement at $1.00 per share, together with common warrants to purchase up to 100,000 shares at an exercise price of $1.00.
The warrants are exercisable immediately and expire on November 6, 2028. Following the transaction, Pons beneficially owned 359,200 shares directly.
Marpai, Inc. entered a Securities Purchase Agreement for a private placement of 3,850,000 shares of Class A common stock and warrants to purchase up to 7,700,000 shares, priced at $1.00 per share with an accompanying warrant.
The offering is expected to generate approximately $4 million in gross proceeds for working capital and general corporate purposes. Warrants are exercisable immediately at $1.00 per share and have a three‑year term, with customary anti‑dilution provisions. Participants include the Company’s COO and President, the Board’s chairman, and certain directors.
The securities are being issued under Section 4(a)(2) and/or Rule 506(b) of Regulation D, and may not be sold in the U.S. absent registration or an exemption. Purchasers have a six‑month right to include the common and warrant shares in any registration the Company files (other than Rule 145(a) transactions). Closing is expected on or about November 7, 2025, subject to customary conditions.
Marpai, Inc. (MRAI) CEO, Director, and 10% Owner Damien Lamendola reported acquiring 550,000 shares of Class A Common Stock on 10/20/2025 at $0, reflecting vested RSUs.
Following the transaction, he reported 1,350,000 shares held directly and indirect holdings of 6,419,893 shares through HillCour Investment Fund, LLC and 931,674 shares through WellEnterprises USA, LLC, as disclosed in footnotes.
Marpai, Inc. (MRAI) reported an insider equity award. A director acquired 75,000 Class A common shares on 10/20/2025 with a transaction code “A,” indicating an award or grant. The filing notes the shares came from RSUs that were deemed fully vested on the issuance date.
The reported acquisition price was $0.00. Following this transaction, the reporting person beneficially owns 222,000 shares, held directly. This filing records an equity compensation event and updates the insider’s holdings.
Marpai, Inc. (MRAI) — Director equity award
Director Yaron Eitan acquired 125,000 shares of Class A Common Stock on 10/20/2025 at a reported price of $0, reflecting settlement of RSUs that were deemed fully vested on the issuance date. Following the transaction, he beneficially owned 989,073 shares, held directly.
Marpai, Inc. (MRAI) reported an insider equity transaction. A director acquired 50,000 shares of Class A common stock on 10/20/2025 at a reported price of $0.00, reflecting settlement of RSUs that were deemed fully vested on the issuance date.
Following the transaction, the reporting person beneficially owns 175,000 shares, held directly. The filing was made on Form 4 and indicates the transaction type as an acquisition.
Marpai, Inc. (MRAI) reported an insider transaction on a Form 4. The Chief Financial Officer acquired 275,000 shares of Class A common stock on 10/20/2025 at $0, issued as RSUs that were fully vested on the issuance date. Following this award, the officer beneficially owns 898,092 shares, held directly.